1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Medical specialties
EKF Diagnostics Holdings plc

EKF Diagnostics Holdings plc

24.30
GBX
+0.05
(+0.21%)
11.45BMarket Cap
Mar 30Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.12
0.1
0.07
0.09
0.09
0.09
0.1
0.14
0.18
0.15
0.12
0.11
0.12
- -
Basic EPS, GAAP
- -
-0.01
-0.09
- -
0.01
0.02
0.01
0.02
0.03
-0.02
0.01
0.01
- -
- -
Free Cash Flow per Basic Share
- -
-0.02
-0.02
0.02
0.01
0.01
0.01
0.02
0.01
0.01
- -
0.02
0.02
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
0.01
0.01
0.01
0.01
- -
- -
- -
Book Value per Share
0.15
0.21
0.11
0.13
0.13
0.14
0.16
0.17
0.2
0.16
0.15
0.16
0.16
0.16
Tangible Book Value per Share
0.02
-0.02
0.01
0.03
0.04
0.05
0.07
0.09
0.11
0.09
0.08
0.1
0.09
0.09
Basic Weighted Avg Shares
272
380
422
446
463
457
454
455
457
457
454
454
448
443
Sales/Revenue/Turnover
32
37
30
39
42
43
45
65
82
67
53
50
52
- -
Operating Margin (%)
7.55
-5.23
-47.76
-0.85
11.37
28.67
12.88
25.89
26.69
2.67
8.24
12.52
13.53
- -
Depreciation Expense
4
5
8
5
5
4
4
5
6
7
5
5
5
- -
Net Income, GAAP
-1
-6
-37
- -
3
10
4
11
16
-10
2
6
2
- -
Effective Tax Rate (%)
247.12
- -
- -
- -
31.74
15.34
28.74
25.86
24.62
- -
- -
- -
64.28
- -
Profit Margin (%)
-3.54
-15.33
-123.56
-0.05
6.53
23.76
8.19
17.03
19.37
-15.16
4.47
12.44
4.12
- -
Working Capital
6
7
-3
7
9
10
14
25
34
20
16
22
23
23
LT Debt
2
2
1
1
1
1
1
1
2
1
1
1
1
1
Total Equity
41
87
47
61
60
64
71
78
95
75
68
73
70
70
Return on Invested Capital (%)
-8.06
- -
- -
- -
4.91
15.96
5.81
15.99
18.07
- -
- -
- -
3.36
- -
Return on Capital (%)
-4.45
- -
- -
- -
3.99
15.73
5.04
14.28
17.61
- -
- -
- -
2.42
- -
Return on Common Equity (%)
-2.84
-8.93
-55.61
-0.03
4.51
16.37
5.49
15
18.46
-12.06
3.35
8.95
3
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
454
449
434
Market Capitalization
123
120
115

Working Capital

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
29
32
31
Cash, Cash Equivalents & STI
13
15
14
Accounts Receivable, Net
6
7
5
Inventories
7
8
8
Total Current Liabilities
6
7
7
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.12%
-1.07%
-4.01%
Free Cash Flow
-189.49%
-393.24%
-32.66%
Net Income, GAAP
-1,501.73%
-29%
-66%
Sales/Revenue/Turnover
7.33%
-3.22%
2.73%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
53
2024
- -
- -
50
2025
- -
- -
52

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.01
2024
- -
- -
0.01
2025
- -
- -
- -

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.01
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Gavin Joseph Jones
Full Time Employees
301
Sector
Health technology
Industry
Medical specialties
Address
Avon House Penarth United Kingdom CF64 2EZ
IPO Date
Jun 5, 2002
Website
ekfdiagnostics.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
EKF Diagnostics Holdings plc is an AIM-listed diagnostics company focused on the development, manufacture, and distribution of point-of-care testing devices, in-vitro diagnostic tests, central laboratory reagents, and life sciences products including enzymes, reagents, and contract manufacturing services. The company offers point-of-care analyzers for hemoglobin, hematocrit, HbA1c, glucose, lactate, and beta-hydroxybutyrate (β-HB) such as the Hemo Control, Quo-Test A1c, Quo-Lox, and related consumables; central laboratory tests and media for high-throughput analysis; and biotechnology components for research, pharmaceuticals, and precision medicine applications. EKF serves healthcare providers including hospitals, clinics, blood banks, and laboratories, as well as research and industrial customers; it manufactures at facilities in the United States and Germany, with distribution to over 120 countries worldwide. Founded through its core operations originating in 1990 and incorporated as a public limited company on 7 January 2002, EKF Diagnostics Holdings plc maintains its headquarters at Avon House, 19 Stanwell Road, Penarth, Cardiff, CF64 2EZ, United Kingdom. In recent developments, EKF reports strong growth in its hematology segment, with a 60% increase in analyzer production during the first half of 2025 versus the prior year, alongside post-period contract wins valued at €4.65 million (approximately £4.03 million) for hemoglobin analyzers and consumables in Latin America and Africa to be delivered over the next 12 to 24 months. The company advances production capacity expansions, including a planned 30% further increase at its Barleben, Germany site to support consumable pull-through and organic growth under its five-year strategic plan; β-HB sales rose 12% (16% on constant currency) in the first half, driven by partner conversions to own-label products. EKF pursues additional life sciences opportunities, anticipating at least one significant new partnership in the second half of 2025, while maintaining share buyback programs including purchases of 700,000 shares in March 2025 and further activity in November 2025.

Company News

Company News APIChatGPT

  • defenseworld.net

    EKF Diagnostics (EKDHF) Projected to Post Earnings on Tuesday

  • defenseworld.net

    EKF Diagnostics (OTCMKTS:EKDHF) Stock Price Up 0.9% – Should You Buy?

  • seekingalpha.com

    EKF Diagnostics Holdings plc (EKDHF) Q2 2025 Earnings Call Transcript